|
Dr. Susan Langer has over 20 years of experience in the pharmaceutical industry, where she has held leadership positions in a number of key functional areas, including clinical development, worldwide strategic planning and franchise management, worldwide product labeling, and global pharmacovigilance.
Prior to joining Iroko Pharmaceuticals, Dr. Langer was Executive Director, Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb, where she was responsible for safety assessment and reporting for cardiovascular and metabolic products throughout all stages of development and commercialization. Also at BMS, she was Vice-President, Neurosciences Strategic Planning and Franchise Management. This role included directing market research, identifying early- and late-stage licensing opportunities, developing internal research strategies, and guiding development and commercialization strategies, resulting in the acquisition, development, approval and successful commercialization of one of the largest-selling new treatments for schizophrenia and bipolar disorder. Prior to joining BMS, Dr. Langer was Executive Director and Head, Neurosciences Clinical Development at Sandoz Pharmaceutical Research, and previously was Director, Neurosciences Clinical Research at Searle.
Dr. Langer is a board-certified psychiatrist who received her M.D. from the University of Rochester School of Medicine. She completed a medical internship and residency in psychiatry at Yale-New Haven Affiliated Hospitals, and was Chief Resident in child psychiatry at Children's Hospital Medical Center /Harvard Medical School. | 